These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 35217809)

  • 41. Primary Biliary Cholangitis and Bile Acid Farnesoid X Receptor Agonists.
    Abenavoli L; Procopio AC; Fagoonee S; Pellicano R; Carbone M; Luzza F; Invernizzi P
    Diseases; 2020 Jun; 8(2):. PubMed ID: 32532037
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The identification of farnesoid X receptor modulators as treatment options for nonalcoholic fatty liver disease.
    Fiorucci S; Biagioli M; Baldoni M; Ricci P; Sepe V; Zampella A; Distrutti E
    Expert Opin Drug Discov; 2021 Oct; 16(10):1193-1208. PubMed ID: 33849361
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis.
    Harrison SA; Bashir MR; Lee KJ; Shim-Lopez J; Lee J; Wagner B; Smith ND; Chen HC; Lawitz EJ
    J Hepatol; 2021 Jul; 75(1):25-33. PubMed ID: 33581174
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Potential of Intestine-Selective FXR Modulation for Treatment of Metabolic Disease.
    van Zutphen T; Bertolini A; de Vries HD; Bloks VW; de Boer JF; Jonker JW; Kuipers F
    Handb Exp Pharmacol; 2019; 256():207-234. PubMed ID: 31236687
    [TBL] [Abstract][Full Text] [Related]  

  • 45. SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis.
    Zhou J; Cui S; He Q; Guo Y; Pan X; Zhang P; Huang N; Ge C; Wang G; Gonzalez FJ; Wang H; Hao H
    Nat Commun; 2020 Jan; 11(1):240. PubMed ID: 31932588
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis.
    Goto T; Itoh M; Suganami T; Kanai S; Shirakawa I; Sakai T; Asakawa M; Yoneyama T; Kai T; Ogawa Y
    Sci Rep; 2018 May; 8(1):8157. PubMed ID: 29802399
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Glycine-β-muricholic acid antagonizes the intestinal farnesoid X receptor-ceramide axis and ameliorates NASH in mice.
    Jiang J; Ma Y; Liu Y; Lu D; Gao X; Krausz KW; Desai D; Amin SG; Patterson AD; Gonzalez FJ; Xie C
    Hepatol Commun; 2022 Dec; 6(12):3363-3378. PubMed ID: 36196594
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH).
    Tully DC; Rucker PV; Chianelli D; Williams J; Vidal A; Alper PB; Mutnick D; Bursulaya B; Schmeits J; Wu X; Bao D; Zoll J; Kim Y; Groessl T; McNamara P; Seidel HM; Molteni V; Liu B; Phimister A; Joseph SB; Laffitte B
    J Med Chem; 2017 Dec; 60(24):9960-9973. PubMed ID: 29148806
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Chow MD; Lee YH; Guo GL
    Mol Aspects Med; 2017 Aug; 56():34-44. PubMed ID: 28442273
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Discovery of Betulinic Acid Derivatives as Potent Intestinal Farnesoid X Receptor Antagonists to Ameliorate Nonalcoholic Steatohepatitis.
    Zhang C; Liu Y; Wang Y; Ge X; Jiao T; Yin J; Wang K; Li C; Guo S; Xie X; Xie C; Nan F
    J Med Chem; 2022 Oct; 65(19):13452-13472. PubMed ID: 36107013
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment of Nonalcoholic Steatohepatitis by Obeticholic Acid: Current Status.
    Roy PP; Mahtab MA; Rahim MA; Yesmin SS; Islam SB; Akbar SMF
    Euroasian J Hepatogastroenterol; 2022 Jul; 12(Suppl 1):S46-S50. PubMed ID: 36466097
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The pathophysiological function of non-gastrointestinal farnesoid X receptor.
    Yan N; Yan T; Xia Y; Hao H; Wang G; Gonzalez FJ
    Pharmacol Ther; 2021 Oct; 226():107867. PubMed ID: 33895191
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Proglumide Reverses Nonalcoholic Steatohepatitis by Interaction with the Farnesoid X Receptor and Altering the Microbiome.
    Gay MD; Cao H; Shivapurkar N; Dakshanamurthy S; Kallakury B; Tucker RD; Kwagyan J; Smith JP
    Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163821
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bile Acids and FXR: Novel Targets for Liver Diseases.
    Stofan M; Guo GL
    Front Med (Lausanne); 2020; 7():544. PubMed ID: 33015098
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Design, synthesis and biological evaluations of novel farnesoid X receptor (FXR) agonists.
    Zhu Y; Zhang J; Min F; Yang X; Li L; Zhang Y; Hou X; Fang H
    Bioorg Med Chem Lett; 2022 Nov; 76():128993. PubMed ID: 36130662
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer.
    Sun L; Cai J; Gonzalez FJ
    Nat Rev Gastroenterol Hepatol; 2021 May; 18(5):335-347. PubMed ID: 33568795
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients.
    Pockros PJ; Fuchs M; Freilich B; Schiff E; Kohli A; Lawitz EJ; Hellstern PA; Owens-Grillo J; Van Biene C; Shringarpure R; MacConell L; Shapiro D; Cohen DE
    Liver Int; 2019 Nov; 39(11):2082-2093. PubMed ID: 31402538
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Obeticholic acid in primary biliary cholangitis: where we stand.
    Manne V; Kowdley KV
    Curr Opin Gastroenterol; 2019 May; 35(3):191-196. PubMed ID: 30844895
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Obeticholic acid for the treatment of primary biliary cholangitis.
    Ali AH; Lindor KD
    Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Farnesoid X Receptor Protects against Kidney Injury in Uninephrectomized Obese Mice.
    Gai Z; Gui T; Hiller C; Kullak-Ublick GA
    J Biol Chem; 2016 Jan; 291(5):2397-411. PubMed ID: 26655953
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.